

## Eugia – Recall of acyclovir injection

- On December 22, 2022, [Eugia announced](#) a consumer level recall of a single lot of [acyclovir](#) 1000 mg/20 mL due to product complaint of “dark particles” inside the vial.
  - Other acyclovir injection products that are not being recalled are available.
- This recalled lot was distributed nationwide May 2022.

| Product Description   | NDC#         | Lot# (Expiration Date) |
|---|--------------|------------------------|
| Acyclovir sodium injection<br>1000 mg per 20 mL (50<br>mg/mL) | 55150-155-20 | AC22004 (8/2023)       |

- Acyclovir injection is used for the treatment of herpes simplex infections in immunocompromised patients, initial episodes of herpes genitalis, herpes simplex encephalitis, neonatal herpes simplex virus infection, and varicella-zoster infections in immunocompromised patients.
- Patients who have the recalled acyclovir should contact their physician or health care provider if they have experienced any problems that may be related to using the recalled product.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- For any questions regarding this recall, call Qualanex at **1-800-505-9291**.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.